Journey Medical Corp. (DERM)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$4.30-9.09%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · DERM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -65.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 57.4% |
Growth built into the price is above our model estimate.
The price assumes 123.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 8 industry peers
DERM — earnings in line
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…
Why it matters: Emrosi revenue rose from $6.3 million in Q1 to $8.1 million in Q2. Another gain would support the growth story.
Supportive ifIn the November 11 results, Q3 Emrosi revenue is above $8.1 million.
Worry ifIn the November 11 results, Q3 Emrosi revenue is below $8.1 million.
Why it matters: Prescriptions rose from about 30,000 in Q1 to 36,000 in Q2. More growth would show that demand is still rising.
Supportive ifThe Q3 report shows more than 36,000 Emrosi prescriptions.
Worry ifThe Q3 report shows 36,000 or fewer Emrosi prescriptions.
Why it matters: Cash was $25.6 million at June 30, down from $27.2 million at March 31. A further drop would raise concern about funding needs.
Worry ifThe November 11 report shows cash below $25.6 million.
Less concerning ifThe November 11 report shows cash at or above $25.6 million.
Why it matters: The company reported a $0.3 million net loss in Q2 and positive adjusted EBITDA in both Q1 and Q2. More progress would support its path toward profit.
Supportive ifThe Q3 report shows positive operating cash flow and a net loss smaller than $0.3 million.
Worry ifThe Q3 report shows negative operating cash flow or a net loss above $0.3 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$214 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $651 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,259 loss on $10,000 · 52.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.